Detalhe da pesquisa
1.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med;
378(6): 518-528, 2018 02 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29231133
2.
Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
Ann Hematol;
98(12): 2805-2814, 2019 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31620815
3.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med;
372(1): 30-9, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25399551
4.
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk;
21(1): 46-54.e4, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33485428
5.
Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.
Cancer Chemother Pharmacol;
77(4): 807-17, 2016 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26940938